Prognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in a High-Risk Population

Receiver operating characteristic analysis

PING XU, MPH1
CRAIG A. BEAM, PHD1
DAVID CUTHBERTSON, MS1
JAY M. SOSENKO, MD2
JAY S. SKYLER, MD2
JEFFREY P. KRISCHER, PHD1
THE DPT-1 STUDY GROUP

OBJECTIVE—To establish and compare the prognostic accuracy of immunologic and metabolic markers in predicting onset of type 1 diabetes in those with high risk in a prospective study.

RESEARCH DESIGN AND METHODS—A total of 339 subjects from the Diabetes Prevention Trial–Type 1 (DPT-1) parenteral study, who were islet cell antibody (ICA)-positive, with low first-phase insulin response (FPIR) and/or abnormal glucose tolerance at baseline, were followed until clinical diabetes onset or study end (5-year follow-up). The prognostic performance of biomarkers was estimated using receiver operating characteristic (ROC) curve analysis and compared with nonparametric testing of ROC curve areas. Pearson correlation was used to assess the relationship between the markers.

RESULTS—Individually, insulin autoantibody titer, ICA512A titer, peak C-peptide, 2-h glucose, FPIR, and FPIR/homeostasis model assessment of insulin resistance provided modest but significant prognostic values for 5-year risk with a similar level of area under ROC curve ranging between 0.61 and 0.67. The combination of 2-h glucose, peak C-peptide, and area under the curve C-peptide significantly improved the prognostic accuracy compared with any solitary index (P < 0.05) with an area under ROC curve of 0.76 (95% CI 0.70–0.81). The addition of antibody titers and/or intravenous glucose tolerance test (IVGTT) markers did not increase the prognostic accuracy further (P = 0.46 and P = 0.66, respectively).

CONCLUSIONS—The combination of metabolic markers derived from the oral glucose tolerance test improved accuracy in predicting progression to type 1 diabetes in a population with ICA positivity and abnormal metabolism. The results indicate that the autoimmune activity may not alter the risk of type 1 diabetes after metabolic function has deteriorated. Future intervention trials may consider eliminating IVGTT measurements as an effective cost-reduction strategy for prognostic purposes.

Diabetes Care 35:1975–1980, 2012

In prevention trials, assessment of the risk of type 1 diabetes in relatives has been initially based on confirmation of positive circulating islet cell antibodies (ICAs) supplemented by measurement of insulin autoantibodies (IAAs) and evaluation of β-cell function by determination of the first-phase insulin response (FPIR) with an intravenous glucose tolerance test (IVGTT) and/or detection of impaired glucose tolerance (IGT) from an oral glucose tolerance test (OGTT) (1,2). Risk groups based on these measurements were used in the Diabetes Prevention Trial–Type 1 (DPT-1) (3). However, subjects with detectable ICAs and abnormal metabolism may progress at different rates, and in the DPT-1 parenteral trial, a higher rate of progression to diabetes was observed among those with abnormal baseline glucose tolerance than among those with normal baseline glucose tolerance but low FPIR (3). Further characterization of the predictive value of biomarkers for progression to type 1 diabetes is needed.

Subsequent to the use of ICAs and IAA titers to screen subjects for type 1 diabetes prevention trials, other islet cell autoantigens, including GAD65 and the protein tyrosine phosphatase IA-2/AIC512, have been identified, and the relationship of autoantibodies to these antigens in assessment of the risk of type 1 diabetes in first-degree relatives has been investigated in a number of large prospective studies (4–6). However, the use of autoantibody titers in these studies has been largely qualitative, relying on the presence or absence of the antibody rather than using antibodies as continuous variables for prediction. The prediction accuracy of the antibody titers remains unclear.

The combination of predictive markers has the potential to further improve the risk prediction of type 1 diabetes. Sosenko et al. (7,8) developed a risk score based on age, BMI, and the OGTT indexes of total glucose, total C-peptide, and fasting C-peptide derived from autoantibody-positive subjects who were with or without metabolic abnormality determined by either OGTT or FPIR. Xu et al. (9) evaluated the metabolic and immunologic markers individually and suggested that the combination of immunologic and metabolic markers may improve the prognostic accuracy in subjects who were ICA- and IAA-positive, but with normal insulin secretion and normal glucose tolerance (NGT). However, the prognostic accuracy of individual or combined biomarkers in predicting type 1 diabetes in high-risk subjects classified as having a relative with type 1 diabetes, detectable islet autoantibodies, and abnormal glucose metabolism has not been quantified.

In this investigation, we sought to evaluate the prognostic accuracy of the immunologic and metabolic markers for...
Prognostic accuracy of markers for type 1 diabetes

predicting the progression to clinical onset of type 1 diabetes over a 5-year period in a high-risk population using the data from the DPT-1 parenteral study (3). The objective of this study was, therefore, to determine the most useful biomarkers for predicting the onset of diabetes in a population we know to be at high risk because of low FPIR and/or abnormal oral glucose tolerance at baseline.

RESEARCH DESIGN AND METHODS—The DPT-1 initially screened 103,391 relatives of patients with type 1 diabetes for ICAs. Of these, 97,273 were eligible because they did not have diabetes, provided an adequate blood sample, were in the required age range (3–45 years for first-degree relatives and 3–20 years for second-degree relatives), and had a qualifying relative. The staging of the study confirmed ICA positivity, measured IAA status, and assessed FPIR to IVGTT (10). If the subject was ICA-positive, had an FPIR less than threshold on two occasions, or had impaired fasting plasma glucose or IGT as determined by an OGTT, he or she was eligible for the parenteral insulin trial. A total of 339 eligible subjects were randomized and followed until diabetes onset or study end (5-year follow-up). All subjects (and/or their parent) signed a written consent form approved by the participating study center’s human subjects committee (3).

Laboratory measures All assays were performed as previously described (3). Plasma glucose was measured by the glucose oxidize method. C-peptide levels were determined by radioimmunoassay. Measurable C-peptide was considered ≥0.2 ng/mL because this was the lowest level detectable by this method.

The peak C-peptide was the maximum point of all measurements. Area under the curve (AUC) C-peptide was calculated using the trapezoid rule. The definition of risk category by IVGTT was based on FPIR, using the sum of the plasma insulin values of the 1- and 3-min samples. FPIR was above threshold if ≥10th percentile for siblings, offspring, and second-degree relatives (≥100 μU/mL if age ≥8 years; ≥60 μU/mL if age <8 years) and ≥1st percentile for parents (≥60 μU/mL) (11). FPIR above threshold was required for eligibility. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as the fasting insulin (mU/L) × fasting glucose (mmol/L)/22.5 from the mean of fasting insulin at 4 and 10 min and fasting glucose at 4 min before each IVGTT performed. The measurements of fasting glucose, fasting insulin, FPIR, and HOMA-IR come from the IVGTT sample. The presence of cyttoplasmic ICA was determined by indirect immunofluorescence, and the subjects with titers of ≥10 JDF units were considered positive (12). IAAs were measured by competitive liquid-phase radioimmunoassay using polyethylene glycol precipitation. GAD-65A and ICA-512A levels were measured simultaneously by combined GADA and ICA-512A radioimmunoassay. The cut points for positivity were set at indexes of 0.032 and 0.049, respectively.

**Determination of abnormal glucose tolerance, IGT, and diabetes**

Abnormal glucose tolerance (AGT) was determined by impaired fasting glucose or IGT at 2 h. Impaired fasting glucose is defined by a fasting glucose concentration ≥110 and <125 mg/dL. IGT is defined by an elevated 2-h plasma glucose concentration ≥140 and <200 mg/dL (3).

Diabetes was diagnosed according to the American Diabetes Association criteria (13).

**Statistical methods**

The baseline characteristics of subjects were summarized and compared between progressors and nonprogressors by a two-sample test or a Wilcoxon rank sum test. The global performance of each marker measured at baseline (as continuous variables) in predicting progression to type 1 diabetes within 5 years was summarized by the receiver operating characteristic (ROC) AUC, and results were presented as the mean and 95% CI. CIs of AUC that exclude 0.5 were considered to indicate significant results. Multiple logistic regression analysis to predict disease status was used to determine the weight to be given each marker in the model, which was then linearly added to give a value for the combined markers, on which the AUC was calculated. Areas under the ROC curves between the markers were compared by a nonparametric method (14). Pearson correlation was used to assess the correlation between the markers. All tests were two-sided. The P values <0.05 were considered to be statistically significant. Analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC) software.

**RESULTS**—By design, subjects were confirmed ICA-positive with a low FPIR and/or IGT (n = 339), giving them a projected risk of >50% for progression to clinical diabetes over 5 years; the subjects were followed for a median of 3.7 years (interquartile range 2.15–4.76 years). A total of 139 subjects were diagnosed with type 1 diabetes in the follow-up period. The dropout rate was 6.3%. The subjects who were lost to follow-up before the end of the study were considered to be nonprogressors. Progressors demonstrated elevated autoimmune activity compared with nonprogressors at baseline (P < 0.01). Progressors also manifested statistically significant poorer metabolic function at baseline for most measurements, with the exceptions of fasting glucose (P = 0.91), fasting insulin (P = 0.95), and HOMA-IR (P = 0.91) (Table 1).

The performance of each marker in predicting progression to type 1 diabetes within 5 years given as estimated AUC, and its 95% CI is shown in Table 2. ICA titer, GAD-65A titer, fasting insulin, HOMA-IR, and fasting glucose from both IVGTT and OGTT performed poorly and did not demonstrate prognostic ability with lower CI limits of AUC <0.50. FPIR demonstrated significant but moderate prognostic value with an AUC value of 0.61 (95% CI 0.55–0.67), as did FPIR/HOMA-IR with the same AUC value. Peak C-peptide and 2-h glucose derived from OGTT yielded the greatest AUC value of all examined metabolic indexes at 0.67 (0.61–0.72), followed by AUC C-peptide with an AUC value of 0.65 (0.59–0.71). IAA titer and ICA-512A titer were the only two immunologic markers that provided significant prognostic value with AUC values of 0.66 (0.60–0.72) and 0.63 (0.56–0.69), respectively. In nonparametric comparison of ROC curve areas, no significant difference was found among IAA titer, ICA-512A titer, FPIR, FPIR/HOMA-IR, peak C-peptide, AUC C-peptide, and 2-h glucose. As well, these markers had significantly higher predictive accuracy than ICA titer, GAD-65A titer, fasting glucose, fasting insulin, and HOMA-IR (P < 0.001) individually.

We further evaluated the prognostic accuracy of the combined markers. The relationship among the markers was first evaluated with correlation analysis (Table 3). With the exception of the high correlation between peak C-peptide and AUC C-peptide (r = 0.96), the magnitude of the correlation among the markers was low or nonsignificant. Multivariate logistic regression modeling was then used to evaluate the overall prognostic performance of the combined markers (Table 2). The AUC
AUC C-peptide, OGTT 0.65 (0.59–0.72)  
Peak C-peptide, OGTT 0.320 (0.019–0.846)  
ICA512A titer (median) 0.230 (0.019–0.846)  
GADA titer (median) 0.280 (0.068–0.813)  
ICA512 antibodies [n (%)]  
Positive 81 (58.27)  
GADA antibodies [n (%)]  
Positive 102 (73.38)  
Metabolic markers  
Fasting glucose, IVGTT (mg/dL) 88.56 (10.98)  
Fasting insulin, IVGTT (mU/L) 11.35 (5.48)  
HOMA-R, IVGTT 2.54 (1.39)  
Fasting glucose, OGTT (mg/dL) 134.95 (33.23)  
Peak C-peptide, OGTT (nmol/L) 4.23 (1.95)  
AUC C-peptide, OGTT (nmol/L) 385.36 (170.24)  

Data are mean (SD), n (%), or median (interquartile range).

Table 2—AUC estimate and its 95% CI for the performance of individual or combined markers in predicting type 1 diabetes within 5 years

| Marker/testing | Overall (n = 339) | Abnormal OGTT (n = 118) | Low FPIR (n = 221) |
|---------------|-----------------|-----------------------|------------------|
| ICA titer, antibody | 0.35 (0.28–0.44) | 0.39 (0.29–0.50) | 0.32 (0.25–0.39) |
| Fasting glucose, IVGTT | 0.52 (0.46–0.58) | 0.52 (0.41–0.62) | 0.49 (0.41–0.58) |
| Fasting insulin, IVGTT | 0.53 (0.47–0.60) | 0.49 (0.38–0.60) | 0.52 (0.44–0.60) |
| HOMA-R, IVGTT | 0.55 (0.48–0.61) | 0.50 (0.39–0.61) | 0.53 (0.44–0.61) |
| Fasting glucose, OGTT | 0.55 (0.48–0.61) | 0.49 (0.38–0.60) | 0.52 (0.44–0.60) |
| GAD65 titer, antibody | 0.55 (0.49–0.62) | 0.51 (0.40–0.61) | 0.54 (0.46–0.62) |
| FPIR, IVGTT | 0.61 (0.55–0.67) | 0.64 (0.53–0.74) | 0.62 (0.54–0.70) |
| FPIR/HOMAR, IVGTT | 0.61 (0.55–0.67) | 0.63 (0.53–0.73) | 0.58 (0.50–0.66) |
| IAA titer, antibody | 0.64 (0.61–0.72) | 0.41 (0.31–0.52) | 0.69 (0.62–0.77) |
| ICA512A titer, antibody | 0.64 (0.57–0.70) | 0.61 (0.50–0.71) | 0.63 (0.54–0.71) |
| 2-h glucose, OGTT | 0.67 (0.61–0.72) | 0.61 (0.51–0.72) | 0.58 (0.50–0.66) |
| Peak C-peptide, OGTT | 0.67 (0.61–0.72) | 0.63 (0.53–0.73) | 0.74 (0.68–0.81) |
| AUC C-peptide, OGTT | 0.65 (0.59–0.71) | 0.62 (0.52–0.73) | 0.72 (0.65–0.79) |
| Combined antibody titer markers* | 0.69 (0.63–0.75) | 0.63 (0.53–0.74) | 0.72 (0.64–0.79) |
| Combined IVGTT markers† | 0.62 (0.56–0.68) | 0.65 (0.55–0.75) | 0.62 (0.54–0.70) |
| Combined OGTT markers and antibody titer markers‡ | 0.70 (0.64–0.76) | 0.71 (0.61–0.80) | 0.73 (0.65–0.80) |
| Combined OGTT markers and antibody titer markers§ | 0.76 (0.70–0.81) | 0.76 (0.69–0.82) | 0.76 (0.69–0.83) |
| Combined OGTT markers and antibody titer markers and IVGTT markers | 0.80 (0.73–0.87) | 0.76 (0.66–0.86) | 0.79 (0.73–0.86) |

*Model includes two antibody titer markers (IAA and ICA512A). †Model includes two IVGTT markers (FPIR and FPIR/HOMA-IR). ‡Model includes three OGTT markers (2-h glucose, peak C-peptide, and AUC C-peptide).
did not increase the prediction accuracy beyond antibody titer and OGTT markers, resulting in an AUC of 0.79 (0.71–0.84). Interestingly, adding age, sex, BMI, and relationship to proband (if sibling) with the biomarkers did not affect the prediction accuracy.

Analyses were also done for two subgroups: one with AGT and another with NGT but loss of FPIR. The AUCs with 95% CIs for individual markers are listed in Table 2. In the subgroup with AGT (n = 118), the OGTT markers (2-h glucose, peak C-peptide, and AUC C-peptide) provided similar levels of predictive accuracy as the IVGTT markers (FPIR and FPIR/HOMA-IR) and ICA512A titers. Interestingly, IAA had poor predictive performance in this subgroup. The AUC derived from the combination of antibody titers and OGTT markers was 0.76 (0.66–0.86); the AUC derived from the combination of antibody titers, OGTT, and IVGTT markers was 0.75 (0.66–0.84). The two AUCs were not significantly different (P = 0.89). In the subgroup with loss of FPIR (n = 221), both peak C-peptide and AUC C-peptide provided significantly higher predictive accuracy than FPIR or FPIR/HOMA-IR (P < 0.03). Peak C-peptide, AUC C-peptide, and IAA titers were better markers than 2-h glucose in predicting disease onset in this subgroup (P = 0.01, P = 0.01, and P = 0.03, respectively). The AUC derived from the combination of antibody titers and OGTT markers was 0.79 (0.73–0.86); the AUC derived from the combination of antibody titers, OGTT, and IVGTT markers was 0.80 (0.73–0.86). The two AUCs did not differ (P = 0.66).

CONCLUSIONS—This investigation into the natural history of type 1 diabetes, using the data from a large, contemporary prevention trial, characterizes the prognostic value of immunologic and metabolic markers in predicting progression to type 1 diabetes in a high-risk population who had demonstrated ICAs and experienced either loss of FPIR or AGT. These findings complement a previous research publication evaluating the metabolic markers in a low-risk population using DPT-1 oral trial subjects (9). The results of this secondary analysis of DPT-1 data reinforce the current paradigm of disease progression from abnormal metabolic activity to overt diabetes as a progressive deterioration of β-cell function, leading to a decline in insulin production and an elevation in glucose level (15–20). Although the previous studies have shown that an increase in insulin resistance was associated with the risk of type 1 diabetes, our findings demonstrate that HOMA-IR did not add to the prognostic value beyond FPIR in high-risk subjects (Table 2) (21–24). This may be due to high-risk subjects being in a later stage of preclinical disease development in which altered insulin secretion is a far more dominant feature relative to subtle insulin resistance.

The prognostic accuracy of OGTT glucose markers evaluated in this investigation was concordant with previous findings investigating the predictive value of metabolic markers for subjects without metabolic abnormality. In both populations with or without abnormal metabolism, 2-h glucose was found to have similar levels of accuracy as IVGTT FPIR/HOMA-IR in predicting type 1 diabetes. However, two other OGTT markers (peak C-peptide and AUC C-peptide) and one other IVGTT marker (FPIR) produced more robust results in high-risk subjects. This is likely due to the subjects being in a more advanced preclinical stage of disease progression such that the predictive value of insulin secretion had become more apparent (9). In contrast to the current analysis, the previous findings of Xu et al. (9) that examined a population positive for ICAs, but with normal metabolic function (possibly indicating an earlier preclinical stage of disease), peak C-peptide, and AUC C-peptide were not found to have predictive value. This suggests that the predictive value derived from these metabolic markers varies at different time points, depending on the stage of disease progression. Future investigations may be interested in examining a time-dependent ROC method for analysis. The lack of predictive value found for fasting glucose in the current analysis remained consistent with the findings in a low-risk population. Although fasting glucose may be preferred because it is convenient and low in cost, it did not provide significant prognostic accuracy in either population. This may be attributed to the fact that the majority of subjects in this population were diagnosed earlier in the course of the disease based on elevated 2-h glucose level but before elevated fasting glucose was detected.

When the immunologic markers were evaluated as quantitative variables, IAA titer and ICA512A titer demonstrated significantly better predictive performance than ICA titer or GADA titer in this population. However, the accuracy from individual or combined antibody titer markers was modest. Adding the antibody titer markers to the OGTT prediction model did not significantly improve the accuracy. Moreover, IAA titer was found not to provide significant prediction value in the subgroup that had AGT. These results indicate that autoimmune activity may not alter the risk of type 1 diabetes after the metabolic function has deteriorated.

In a previous study by Barker et al. (24), abnormalities in 2-h glucose from an OGTT were as sensitive and had better specificity in predicting diabetes compared with loss of FPIR. Our results from the subgroup analyses indicated that OGTT markers (peak C-peptide or AUC C-peptide) provided similar accuracy as FPIR levels in the subjects with AGT and had better prediction than
measurements are the most ef-
metabolic markers derived from OGTT
OGTT in both the AGT group and NGT
test are considered robust because a nonparametric approach was used for the comparisons, which elim-
the need for applying assumptions on the underlying distribution.

Accurate prognostication is depend-
acterived from autoantibodies among cytoplas-

OGTT markers assess the efficiency of the body to metabolize glucose and have been used as the gold standard for di-
OGTT measurements (25). Thus, in a future study that relies on OGTT markers, within-subject variability can potentially affect sample size requirements, study procedures, and overall study costs. Con-
consideration of this factor would need to be given when using the results of the cur-
ROC analysis provides the most compre-

is sufficient to provide adequate statistical power (≥80%) to detect a 10% of differ-
ence in the AUC ROC of the biomarkers. Additionally, the tests are considered robust because a nonparametric approach was used for the comparisons, which elim-

Acknowledgments—The DPT-1 was spon-
sored by the National Institute of Diabetes and Di-

References
1. Bingley PJ, Bonifacio E, Ziegler A-G, Schatz DA, Atkinson MA, Eisenbarth GS. Immunology of Diabetes Society. Proposed guidelines on screening for risk of type 1 diabetes. Diabetes Care 2001;24:398
2. DPT-1 Study Group. The Diabetes Preven-
tion Trial-Type 1 Diabetes (DPT-1): im-
plementation of screening and staging of relatives. DPT-1 Study Group. Transplant Proc 1995;27:3377
3. Diabetes Prevention Trial–Type 1 Di-
abetes Study Group. Effects of insulin in rela-
tives of patients with type 1 diabetes melitus. N Engl J Med 2002;346:1685–
1691
4. Yu L, Cuthbertson DD, McLauren N, et al.; DPT-1 Participating Investigators. Ex-
pression of GAD65 and islet cell antibody (ICA512) autoantibodies among cytoplas-
mic ICA+ relatives is associated with eligi-
bility for the Diabetes Prevention Trial-Type 1. Diabetes 2001;50:1735–1740
5. Wasserman C, Atkinson MA. Autoantibody markers for the diagnosis and prediction of type 1 diabetes. Autoimmune Rev 2006;5:424–428
6. Mrena S, Virtanen SM, Laippala P, et al.; The Childhood Diabetes In Finland Study Group. Models for predicting type 1 diabetes in siblings of affected children. Diabetes Care 2006;29:662–667
7. Sosenko JM, Palmer JP, Greenbaum CJ, et al.; Diabetes Prevention Trial-Type 1 Study Group. Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 2007;30:38–42
8. Sosenko JM, Krischer JP, Palmer JP, et al.; Diabetes Prevention Trial-Type 1 Study Group. A risk score for type 1 diabetes derived from autoantibody-positive partic-

DPT-1 Participating Investigators. Ex-

DPT-1 Study Group. The Diabetes Preven-
tion Trial of Type 1 Diabetes (DPT-1) (Abstract). Diabetes 1994;43(Suppl. 1): 159A
11. Bingley PJ, Colman P, Eisenbarth GS, et al. Standardization of IVGTT to predict IDDM. Diabetes Care 1992;15:1313–1316
12. Schatz D, Krischer J, Horne G, et al. Islet cell antibodies predict insulin-dependent diabetes in United States school age chil-
dren as powerfully as in unaffected rela-
tives. J Clin Invest 1994;93:2403–2407
13. American Diabetes Association Expert Committee on the Diagnosis and Classi-
cification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–1197
14. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteris-
care.diabetesjournals.org

Diabetes Care 2006;29:662–667
The Childhood Diabetes In Finland Study Group. Models for predicting type 1 diabetes in siblings of affected children. Diabetes Care 2007;30:38–42
Diabetes Prevention Trial-Type 1 Study Group. A risk score for type 1 diabetes derived from autoantibody-positive partic-
participants in the diabetes prevention tria-
1 diabetes. Diabetes Care 2008;31:528–533
Xu P, Wu YG, Zhu YL, et al.; Diabetes Prevention Trial-Type 1 Study Group. Prognostic performance of meta-
fined on type 1 diabetes. Diabetes Care 2010;33:2508–
2513
DPT-1 Study Group. The Diabetes Preven-
tion Trial of Type 1 Diabetes (DPT-1) (Abstract). Diabetes 1994;43(Suppl. 1): 159A
Standardization of IVGTT to predict IDDM. Diabetes Care 1992;15:1313–1316
Islet cell antibodies predict insulin-dependent diabetes in United States school age children as powerfully as in unaffected rela-
tives. J Clin Invest 1994;93:2403–2407
American Diabetes Association Expert Committee on the Diagnosis and Classi-
cification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–1197
Comparing the areas under two or more correlated receiver operating characteris-
curves: a nonparametric approach. Biometrics 1988;44:837–845
15. Eisenbarth G. Prediction of type 1 diabetes: the natural history of the prediabetic period. In Immunology of Type 1 Diabetes. 2nd ed. Eisenbarth GS, Ed. New York, Springer Publishing, 2004, p. 268–281
16. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: report of an ADA workshop, 21–22 October 2001. Diabetes 2004;53:250–264
17. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008;31:2188–2192
18. Ferrannini E, Mari A, Nofrata V, Sosenko JM, Skyler JS, DPT-1 Study Group. Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes 2010;59:679–685
19. Sosenko JM, Palmer JP, Rafkin LE, et al.; Diabetes Prevention Trial-Type 1 Study Group. Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 participants. Diabetes Care 2010;33:620–625
20. Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 2004;47:1661–1667
21. Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP; Diabetes Prevention Trial-Type 1 Study Group. Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care 2007;30:2314–2320
22. Greenbaum CJ. Insulin resistance in type 1 diabetes. Diabetes Metab Res Rev 2002;18:192–200
23. Acerini CL, Cheetham TD, Edge JA, Dunger DB. Both insulin sensitivity and insulin clearance in children and young adults with type 1 (insulin-dependent) diabetes vary with growth hormone concentrations and with age. Diabetologia 2000;43:61–68
24. Barker JM, McFann K, Harrison LC, et al.; DPT-1 Study Group. Pre-type 1 diabetes dysmetabolism: maximal sensitivity achieved with both oral and intravenous glucose tolerance testing. J Pediatr 2007;150:31–36, e6
25. Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 2007;167:1545–1551